MERS-CoV vaccine
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
1. An immunogenic composition comprising a nucleic acid molecule, wherein:
(a) the nucleic acid molecule comprises a nucleic acid sequence having at least about 90% identity over an entire length of the nucleic acid sequence set forth in SEQ ID NO:1; or
(b) the nucleic acid molecule comprises a nucleic acid sequence having at least about 90% identity over an entire length of the nucleic acid sequence set forth in SEQ ID NO:3.
2. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:3.
3. The immunogenic composition of claim 1 , further comprising:
(a) a peptide comprising an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2; or
(b) a peptide comprising an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:4.
4. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises an expression vector.
5. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.
6. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
7. The immunogenic composition of claim 1 , further comprising an adjuvant.
8. The immunogenic composition of claim 1 , wherein the nucleic acid molecule encodes a peptide comprising the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.
9. An immunogenic composition comprising a nucleic acid molecule, wherein:
a) the nucleic acid molecule encodes SEQ ID NO:2;
or
b) the nucleic acid molecule encodes SEQ ID NO:4.
10. The immunogenic composition of claim 9 , further comprising:
a) a peptide comprising an amino acid sequence as set forth in SEQ ID NO:2; or
b) a peptide comprising an amino acid sequence as set forth in SEQ ID NO:4.
11. The immunogenic composition of claim 9 , wherein the nucleic acid molecule comprises an expression vector.
12. The immunogenic composition of claim 9 , wherein the nucleic acid molecule is incorporated into a viral particle.
13. The immunogenic composition of claim 9 , further comprising a pharmaceutically acceptable excipient.
14. The immunogenic composition of claim 9 , further comprising an adjuvant.
15. A nucleic acid molecule comprising the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:3.
16. A peptide comprising the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.
17. An immunogenic composition comprising an antigen 17 , wherein the antigen comprises the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4.
18. The immunogenic composition of claim 17 , wherein the antigen is encoded by SEQ ID NO: 1 or SEQ ID NO: 3.
19. An immunogenic composition comprising a peptide, wherein a) the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 2; or b) the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 4.
20. A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering an immunogenic composition of claim 1 to the subject.
21. The method of claim 20 , wherein administering includes at least one of electroporation and injection.
22. A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering an immunogenic composition of claim 1 to the subject.
23. The method of the claim 22 , wherein administering includes at least one of electroporation and injection.
24. A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering an immunogenic composition of claim 1 to the subject, wherein the subject is thereby resistant to one or more MERS-CoV strains.
25. The method of claim 24 , wherein administering includes at least one of electroporation and injection.